Raloxifene in the Treatment of Osteoporosis in Postmenopausal Women with End-Stage Renal Disease: A Systematic Review and Meta-Analysis

Abstract

As a selective estrogen receptor modulator (SERM), raloxifene is used in healthy postmenopausal women to prevent bone loss and reduce fractures. However, the benefit of raloxifene is uncertain in the treatment of osteoporosis among patients with end-stage renal disease (ESRD) or those who require maintenance dialysis. We assessed the safety and efficacy of raloxifene in this particular population. Studies were selected from PubMed, Springer, CNKI (Chinese National Knowledge Infrastructure) and Wanfang Database. Randomized controlled trials (RCTs) and prospective studies with control/placebo groups were included. Five studies were included with a total of 244 participants (121 patients in the raloxifene group and 123 patients in the placebo/control group). The median duration of treatment was 12 months. The incidence rate of side effects of raloxifene was 0/121 (0%). There was a significant improvement of lumbar spine bone mineral density (BMD) levels in the raloxifene group compared with the placebo group (MD: 33.88, 95% CI: 10.93, 56.84, p=0.004). There was no significant difference concerning the improvement of femoral neck BMD (MD: 8.42, 95% CI: –10.21, 27.04, p=0.38), intact parathyroid hormone (iPTH) (MD: –12.62, 95% CI: –35.36, 10.13, p=0.28), calcium (MD: -0.08, 95% CI: –0.61, 0.44, p=0.76), phosphorus (MD: 0.18, 95% CI: –0.12, 0.48, p=0.23) or bone alkaline phosphatase (BAP) (MD: –4.33, 95% CI: –14.44, 5.79, p=0.40). Raloxifene seems to be effective in improving the lumbar spine BMD in postmenopausal women with ESRD. More large RCTs are necessary to evaluate the long-term safety of raloxifene in uremic patients.

Key words

osteoporosis - osteopenia - postmenopause - end-stage renal disease - raloxifene

Publication History

Received: 06 April 2020

Accepted after revision: 16 September 2021

Article published online:
05 November 2021

• References

• 1 Wright NC, Saag KG, Dawson-Hughes B. et al. The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA. Osteoporos Int 2017; 28: 1225-1232
• 2 Cipriani C, Pepe J, Bertoldo F. et al. The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study. J Endocrinol Invest 2018; 41: 431-438
• 3 Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Eng J Med 2016; 374: 254-262
• 4 Miyauchi Y, Sato Y, Kobayashi T. et al. HIF1a is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc Natl Acad Sci USA 2013; 110: 16568-16573
• 5 Raehtz S, Bierhalter H, Schoenherr D. et al. Estrogen deficiency exacerbates type 1 diabetes-induced bone TNF-a expression and osteoporosis in female mice. Endocrinology 2017; 158: 2086-2101
• 6 Brennan M, Haugh MG, O'Brien FJ. et al. Estrogen withdrawal from osteoblasts and osteocytes causes increased mineralization and apoptosis. Horm Metab Res 2014; 46: 537-545
• 7 Percegoni N, Ferreira AC, Rodrigues CF. et al. Profile of serum IL-1beta and IL-10 shortly after ovariectomy and estradiol replacement in rats. Horm Metab Res 2009; 41: 5054
• 8 Brennan O, O'Brien FJ, McNamara LM. Estrogen plus estrogen receptor antagonists alter mineral production by osteoblasts in vitro. Horm Metab Res 2012; 44: 47-53
• 9 Nitta K, Yajima A, Tsuchiya K. Management of osteoporosis in chronic kidney disease. Intern Med (Tokyo, Japan) 2017; 56: 3271-3276
• 10 Bover J, Bailone L, López-Báez V. et al. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol 2017; 30: 677-687
• 11 Chiang C. The use of bone turnover markers in chronic kidney disease-mineral and bone disorders. Nephrology (Carlton, Vic) 2017; 22: 11-13
• 12 Dooley AC, Weiss NS, Kestenbaum B. Increased risk of hip fracture among men with CKD. Am J Kidney Dis 2008; 51: 38-44
• 13 Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 2006; 17: 3223-3232
• 14 Jansz TT, Goto NA, van Ballegooijen AJ. et al. The prevalence and incidence of vertebral fractures in end-stage renal disease and the role of parathyroid hormone. Osteoporos Int 2020; 31: 515-524
• 15 Alem AM, Sherrard DJ, Gillen DL. et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 396-399
• 16 Ensrud KE, Lui LY, Taylor BC. et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 2007; 167: 133-139
• 17 LaCroix AZ, Lee JS, Wu L. et al. Cystatin-C, renal function, and incidence of hip fracture in postmenopausal women. J Am Geriatr Soc 2008; 56: 1434-1441
• 18 Waziri B, Duarte R, Naicker S. Chronic kidney disease-mineral and bone disorder (CKD-MBD): Current perspectives. Int J Nephrol Renovasc Dis 2019; 12: 263-276
• 19 Huimin C, Ying C, Changying X. et al. Effects of parathyroidectomy on plasma iPTH and (1-84) PTH levels in patients with stage 5 chronic kidney disease. Horm Metab Res 2018; 50: 761-767
• 20 Miller PD, Jamal SA, Evenepoel P. et al. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Mineral Res 2013; 28: 2049-2059
• 21 Khairallah P, Nickolas TL. Management of osteoporosis in CKD. Clin J Am Soc Nephrol 2018; 13: 962-969
• 22 [Anonymous]. KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2017; 7: 1–59
• 23 Peng L, Luo Q, Lu H. Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: a systematic review and meta-analysis. Medicine 2017; 96: e8659
• 24 Eastell R, Rosen CJ, Black DM. et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2019; 104: 1595-1622
• 25 Melamed ML, Blackwell T, Neugarten J. et al. Raloxifene, a selective estrogen receptor modulator, is renoprotective: A post-hoc analysis. Kidney Int 2011; 79: 241-249
• 26 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol 2009; 62: e1-e34
• 27 Saito O, Saito T, Asakura S. et al. Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes. Int J Endocrinol Metab 2012; 10: 464-469
• 28 [Anonymous]. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. report of a WHO study group. WHO Tech Rep Ser 1994; 843: 1–129
• 29 Hernández E, Valera R, Alonzo E. et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 2003; 63: 2269-2274
• 30 Haghverdi F, Farbodara T, Mortaji S. et al. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5. Iran J kidney Dis 2014; 8: 461-466
• 31 Saito O, Saito T, Asakura S. et al. The effects of raloxifene on bone turnover markers and bone mineral density in women on maintenance hemodialysis. Clin Exp Nephrol 2011; 15: 126-131
• 32 Cumpston M, Li T, Page MJ. et al. Updated guidance for trusted systematic reviews: A new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 2019; 10: Ed000142
• 33 Nagatoya K, Nishimoto K, Shibahara N. et al. Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis. Clin Exp Nephrol 2015; 19: 939-946
• 34 Hadjadj S, Gourdy P, Zaoui P. et al. Effect of raloxifene – a selective oestrogen receptor modulator – on kidney function in post-menopausal women with type 2 diabetes: Results from a randomized, placebo-controlled pilot trial. Diabet Med 2007; 24: 906-910
• 35 Ishani A, Blackwell T, Jamal SA. et al. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 2008; 19: 1430-1438
• 36 Adami S, Palacios S, Rizzoli R. et al. The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status. Climacteric 2014; 17: 273-284
• 37 Ozbasar D, Toros U, Ozkaya O. et al. Raloxifene decreases serum malondialdehyde and nitric oxide levels in postmenopausal women with end-stage renal disease under chronic hemodialysis therapy. J Obstetr Gynaecol Res 2010; 36: 133-137
• 38 Tanaka M, Itoh K, Matsushita K. et al. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis. Therap Apheres Dialysis 2011; 15: 62-66
• 39 Ellis AJ, Hendrick VM, Williams R. et al. Selective estrogen receptor modulators in clinical practice: a safety overview. Expert Opin Drug Safety 2015; 14: 1799-1800
• 40 Honisett SY, Tangalakis K, Wark J. et al. The effects of hormonal therapy and exercise on bone turnover in postmenopausal women: A randomised double-blind pilot study. Prilozi (Makedonska akademija na naukite i umetnostite Oddelenie za medicinski nauki) 2016; 37: 23-32
• 41 Fujita K, Roforth MM, Demaray S. et al. Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women. J Clin Endocrinol Metab 2014; 99: E81-E88
• 42 Uemura H, Kamada M, Maegawa M. et al. Effect of hormone replacement therapy on the production of bone-resorbing cytokines by peripheral blood cells in postmenopausal women. Horm Metab Res 2005; 37: 226-230
• 43 Seeman E. Raloxifene. J Bone Mineral Metab 2001; 19: 65-75
• 44 Mosca L, Grady D, Barrett-Connor E. et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 2009; 40: 147-155
• 45 Khorsand I, Kashef R, Ghazanfarpour M. et al. The beneficial and adverse effects of raloxifene in menopausal women: a mini review. J Menopaus Med 2018; 24: 183-187
• 46 Hruska KA, Choi ET, Memon I. et al. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol (Berlin, Germany) 2010; 25: 769-778
• 47 Molino D, De Lucia D, Gaspare De Santo N. Coagulation disorders in uremia. Sem Nephrol 2006; 26: 46-51
• 48 Cuzick J. Long-term follow-up in cancer prevention trials (It ain't over 'til it's over). Cancer Prevent Res (Philadelphia, Pa) 2010; 3: 689-691
• 49 Siris ES, Adler R, Bilezikian J. et al. The clinical diagnosis of osteoporosis: a position statement from the national bone health alliance working group. Osteoporos Int 2014; 25: 1439-1443
• 50 Ensrud KE, Stock JL, Barrett-Connor E. et al. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Mineral Res 2008; 23: 112-120
• 51 Seeman E, Crans GG, Diez-Perez A. et al. Anti-vertebral fracture efficacy of raloxifene: A meta-analysis. Osteoporos Int 2006; 17: 313-316
• 52 Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med 2006; 119: S25-S31
• 53 Jørgensen HS, Winther S, Bøttcher M. et al. Bone turnover markers are associated with bone density, but not with fracture in end stage kidney disease: a cross-sectional study. BMC Nephrol 2017; 18: 284
• 54 Kaji H, Nomura R, Yamauchi M. et al. The usefulness of bone metabolic indices for the prediction of changes in bone mineral density after parathyroidectomy in patients with primary hyperparathyroidism. Horm Metab Res 2006; 38: 411-416